Energenesis Biomedical Co., Ltd. 6657

TWSE · Taiwan · Health Technology

TWD 32.90+0.30 (+0.92%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Company news

Yahoo FinanceAug 06, 2026

Energenesis Biomedical and Taiwan Tanabe Seiyaku Enter Joint Development Agreement for ENERGI-F703DFU

Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has entered into a joint development agreement with Taiwan Tanabe Seiyaku Co., Ltd. (Taiwan Tanabe), the wholly owned subsidiary of Tanabe Pharma Corporation, for ENERGI-F703DFU, Energenesis' investigational topical drug for diabetic foot ulcers (DFU).

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.

Makkler App

Faster and clearer

Install